Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Common Equity (2018 - 2026)

TransMedics has reported Common Equity over the past 8 years, most recently at $473.1 million for Q4 2025.

  • For Q4 2025, Common Equity rose 106.95% year-over-year to $473.1 million; the TTM value through Dec 2025 reached $473.1 million, up 106.95%, while the annual FY2025 figure was $473.1 million, 106.95% up from the prior year.
  • Common Equity for Q4 2025 was $473.1 million at TransMedics, up from $355.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $473.1 million in Q4 2025 and troughed at $50.9 million in Q2 2022.
  • A 5-year average of $181.1 million and a median of $173.4 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: tumbled 42.78% in 2022 and later surged 221.52% in 2023.
  • Year by year, Common Equity stood at $67.9 million in 2021, then surged by 176.14% to $187.4 million in 2022, then dropped by 26.78% to $137.2 million in 2023, then soared by 66.62% to $228.6 million in 2024, then surged by 106.95% to $473.1 million in 2025.
  • Business Quant data shows Common Equity for TMDX at $473.1 million in Q4 2025, $355.2 million in Q3 2025, and $318.1 million in Q2 2025.